Head and Neck Cancer - Drug Pipeline Analysis and Market Forecasts to 2016

Report Summary

GlobalData, the industry analysis specialist’s new report, “Head and Neck Cancer – Pipeline Assessment and Market Forecast to 2017” is an essential source of information and analysis on the global head and neck cancer market. The report identifies the key trends shaping and driving the global head and neck cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global head and neck cancer sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:  

• Annualized global head and neck cancer market revenues data from 2001 to 2009, forecast forward for 8 years to 2017.
• Geographic markets covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
• Analysis of the current and future market competition in the global head and neck cancer market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with head and neck cancer

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global head and neck cancer market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global head and neck cancer market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global head and neck cancer market landscape? – Identify, understand and capitalize.

1 Table of contents 3

1.1 List of Tables 5
1.2 List of Figures 5

2 Head and Neck Cancer Market: Introduction 6
2.1 GlobalData Pipeline Report Guidance 6

3 Head and Neck Cancer Market: Market Characterization 7
3.1 Head and Neck Cancer Market Size 7
3.2 Head and Neck Cancer Market Forecast and CAGR 8
3.3 Drivers and Barriers for Head and Neck Cancer Market 9
3.3.1 Drivers for Head and Neck Cancer Market 9
3.3.2 Barriers for Head and Neck Cancer Therapeutics Market 10
3.4 Opportunity and Unmet Need 10
3.5 Key Takeaway 12

4 Head and Neck Cancer Market: Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Profile for the Major Marketed Products in the Head and Neck Cancer Market 14
4.3.1 Erbitux (cetuximab) 14
4.3.2 Taxotere (docetaxel) 16
4.4 Approved Gene Therapies in China 17
4.4.1 Oncorine (H101, Modified Adenovirus) 17
4.4.2 Gendicine (Recombinant Human Ad-P53) 17
4.5 Key Takeaway 18

5 Head and Neck Cancer Market: Pipeline Assessment 19
5.1 Overview 19
5.2 Strategic Pipeline Assessment 19
5.2.1 Technology Trends Analytic Framework 19
5.3 Head and Neck Cancer Therapeutics – Promising Drugs under Clinical Development 21
5.4 Molecule Profile for Promising Drugs under Clinical Development for Head and Neck Cancer 22
5.4.1 Tykerb/ Tyverb (Lapatinib Ditosylate) 22
5.4.2 Reolysin 23
5.4.3 Oncovex 24
5.4.4 Nimotuzumab 25
5.5 Head and Neck Cancer Therapeutics Market – Clinical Pipeline by Mechanism of Action 27
5.6 Head and Neck Cancer Pipeline – Pipeline by Phases of Development 28
5.6.1 Head and Neck Cancer Therapeutics – Regulatory and Phase III Clinical Pipeline 28
5.6.2 Head and Neck Cancer Therapeutics-Phase II Clinical Pipeline 31
5.6.3 Head and Neck Cancer Therapeutics-Phase I Clinical Pipeline 42
5.6.4 Head and Neck Cancer Therapeutics- Preclinical Pipeline 46
5.7 Discontinued / Suspended Drugs for Head and Neck Cancer 46
5.8 Key Takeaway 46

6 Head and Neck Cancer Therapeutics Market: Implications for Future Market Competition 47

7 Head and Neck Cancer Therapeutics Market: Future Players 49
7.1 Introduction 49
7.2 GlaxoSmithKline (GSK) 49
7.2.1 Overview 49
7.2.2 Oncology Pipeline Products 50
7.3 Oncolytics Biotech, Inc. 51
7.3.1 Overview 51
7.3.2 Oncology Pipeline Products 52
7.4 Biovex Inc. 52
7.4.1 Overview 52
7.4.2 Oncology Pipeline Products 52
7.5 AstraZeneca PLC 52
7.5.1 Overview 52
7.5.2 Oncology Pipeline Products 54
7.6 Advaxis, Inc. 54
7.6.1 Overview 54
7.6.2 Oncology Pipeline Products 55
7.7 TapImmune Inc. 55
7.7.1 Overview 55
7.7.2 Oncology Pipeline Products 55
7.8 IRX Therapeutics, Inc. 56
7.8.1 Overview 56
7.8.2 Oncology Pipeline Products 56
7.9 Keryx Biopharmaceuticals, Inc. 56
7.9.1 Overview 56
7.9.2 Oncology Pipeline Products 57
7.10 CEL-SCI Corporation 57
7.10.1 Overview 57
7.10.2 Oncology Pipeline Products 57

8 Head and Neck Cancer Market: Appendix 58
8.1 Market Definitions 58
8.2 Scope of Pipeline Research 58
8.3 Abbreviations 58
8.4 Research Methodology 60
8.4.1 Coverage 60
8.4.2 Secondary Research 60
8.4.3 Forecasting 60
8.4.4 Primary Research 63
8.4.5 Expert Panels 63
8.5 Contact Us 63
8.6 Disclaimer 64
8.7 Sources 64

1.1 List of Tables

Table 1: Head and Neck Cancer Therapeutics Market, Global, Market Revenue ($m), 2001–2009 8
Table 2: Head and Neck Cancer Therapeutics Market, Global, Market Revenue ($m), 2009–2017 9
Table 3: Major Marketed Products Comparison in the Head and Neck Cancer Market, 2010 18
Table 4: Head and Neck Cancer Therapeutics – Most Promising Drugs under Clinical Development, 2010 21
Table 5: Head and Neck Cancer – Regulatory and Phase III Clinical Pipeline, 2010 28
Table 6: Head and Neck Cancer – Phase II Clinical Pipeline, 2010 31
Table 7: Head and Neck Cancer – Phase I Clinical Pipeline, 2010 42
Table 8: Head and Neck Cancer – Preclinical and Discovery Pipeline, 2010 46
Table 9: Discontinued Drugs for Head and Neck Cancer, 2010 46
Table 10: GlaxoSmithKline Plc., Oncology Pipeline Products, 2010 50
Table 11: Oncolytics Biotech Inc., Oncology Pipeline Products, 2010 52
Table 12: BioVex, Inc.,  Oncology Pipeline Products, 2010 52
Table 13: AstraZeneca Plc., Oncology Pipeline Products, 2010 54
Table 14: Advaxis Inc., Oncology Pipeline Products, 2010 55
Table 15: TapImmune Inc., Oncology Pipeline Products, 2010 55
Table 16: IRX Therapeutics, Inc, Oncology Pipeline Products, 2010 56
Table 17: Keryx Biopharmaceuticals, Inc., Oncology Pipeline Products, 2010 57
Table 18: CEL-SCI Corporation, Oncology Pipeline Products, 2010 57

1.2 List of Figures

Figure 1: Head and Neck Cancer Therapeutics Market, Global, Market Revenue ($m), 2001–2009 8
Figure 2: Head and Neck Cancer Therapeutics Market, Global, Market Revenue ($m), 2009–2017 9
Figure 3: Opportunity and Unmet Need in the Head and Neck Cancer Therapeutics Market, 2010 11
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Head and Neck Cancer, 2010 14
Figure 5: Technology Trends Analytic Framework  of the Head and Neck Cancer Pipeline,  2010 20
Figure 6: Technology Trends Analytic Framework of the Head and Neck Cancer Pipeline Description, 2010 20
Figure 7: Head and Neck Cancer – Clinical Pipeline by Mechanism of Action, 2010 27
Figure 8: Head and Neck Cancer Therapeutics Pipeline by Phase of Development, 2010 28
Figure 9: Implications for Future Market Competition in the Head and Neck Cancer Therapeutics Market, 2010 47
Figure 10: Head and Neck Cancer Therapeutics Market, Global, Clinical Pipeline by Company, 2010 49
Figure 11: GlobalData Market Forecasting Model 62